Boswellia Serrata (Indian Frankincense) and Multiple Sclerosis: Patient-Friendly Research Guide

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Boswellia Serrata (Indian Frankincense) and Multiple Sclerosis: A Patient-Friendly Research Overview

If you or a loved one has Multiple Sclerosis and you've heard about Boswellia Serrata (Indian Frankincense), this guide explains what the research actually shows in plain language. We believe patients deserve honest, clear information — not hype, not dismissal. This is a research summary only. Always work with your neurologist.

What is Boswellia Serrata (Indian Frankincense)?

Boswellia Serrata (Indian Frankincense) is classified as a Herbal / Anti-inflammatory. In simple terms, it works by: Inhibits 5-lipoxygenase (5-LOX); reduces pro-inflammatory leukotrienes; anti-inflammatory BAs; inhibits NF-κB...

Its current regulatory status: Dietary supplement; not FDA-approved

Why Are MS Patients Asking About Boswellia Serrata (Indian Frankincense)?

Researchers and patients with MS have explored Boswellia Serrata (Indian Frankincense) because of its specific mechanisms that may be relevant to MS biology. This has generated both scientific publications and patient community interest.

What the Research Actually Shows

Evidence level: RCT evidence for osteoarthritis; Phase II for brain edema reduction; Cochrane review for IBD

This means: There is scientific research specifically examining this combination, providing more than just theoretical interest.

Safety in Plain Language

What you should know about Boswellia Serrata (Indian Frankincense) safety: Generally well tolerated; GI side effects; theoretical interaction with anticoagulants; avoid in pregnancy

Important: even compounds with favorable safety profiles can have risks in MS patients due to interactions with treatment or disease-related organ changes.

Questions to Bring to Your Neurologist

  • Has Boswellia Serrata (Indian Frankincense) been studied for MS? What does the evidence show?
  • Could Boswellia Serrata (Indian Frankincense) interact with my current MS treatment?
  • Are there clinical trials involving Boswellia Serrata (Indian Frankincense) that I might be eligible for?
  • What monitoring would be needed if I were to try Boswellia Serrata (Indian Frankincense)?
  • What are the alternatives that have stronger evidence?

How to Research Further

For continued research: PubMed (pubmed.ncbi.nlm.nih.gov) for peer-reviewed studies, ClinicalTrials.gov for active trials, and insightswarm.ai for a personalized AI-generated research report tailored to your specific case.


Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

Can Boswellia Serrata (Indian Frankincense) cure MS?

No compound has been proven to cure Multiple Sclerosis, and Boswellia Serrata (Indian Frankincense) is no exception. The current evidence for Boswellia Serrata (Indian Frankincense) in MS is: RCT evidence for osteoarthritis; Phase II for brain edema reduction; Cochrane review for IBD. Be cautious of any source claiming a cure.

Is Boswellia Serrata (Indian Frankincense) worth trying for MS?

Whether Boswellia Serrata (Indian Frankincense) is worth considering for your specific MS case is a decision that requires your neurologist's assessment. The published research (RCT evidence for osteoarthritis; Phase II for brain edema reduction; Cochrane review for IBD) can inform that conversation, but individual factors matter enormously.

Where can I learn more about Boswellia Serrata (Indian Frankincense) for MS?

Reliable sources: PubMed for peer-reviewed research, ClinicalTrials.gov for trials, your neurologist, and insightswarm.ai for a personalized research report. Be critical of forums and social media, which often amplify anecdotal reports.